ERBB2 and breast cancer: A further point is the higher presence of HER2 immunostaining in morphologically normal urothelium, either from patients with positive as compared to negative BC history (64% versus 33%) in one study [32], or adjacent to urothelial neoplasms [31], thus suggesting that early molecular changes may precede the development of morphologically detectable features of malignancy.